Clinical practice: Low HDL cholesterol levels

[41] Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12): : 1585 - 1591

[42] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) : 410 - 418

[43] Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects - A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm [J]. DIABETES CARE, 2004, 27 (06) : 1324 - 1329

[44] Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease [J]. ATHEROSCLEROSIS, 1999, 144 (01) : 177 - 184

[45] LOW HIGH-DENSITY-LIPOPROTEIN LEVEL IS ASSOCIATED WITH INCREASED RESTENOSIS RATE AFTER CORONARY ANGIOPLASTY [J]. CIRCULATION, 1992, 85 (04) : 1279 - 1285

[46] Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins - An idea whose time for testing is coming, Part I [J]. CIRCULATION, 2001, 104 (19) : 2376 - 2383

[47] Slyper A, 2005, AM J CLIN NUTR, V81, P376

[48] Mechanism of action of fibrates on lipid and lipoprotein metabolism [J]. CIRCULATION, 1998, 98 (19) : 2088 - 2093

[49] Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (01) : 12 - 20

[50] Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [J]. CIRCULATION, 2004, 110 (23) : 3512 - 3517

[41] Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12): : 1585 - 1591

[42] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) : 410 - 418

[43] Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects - A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm [J]. DIABETES CARE, 2004, 27 (06) : 1324 - 1329

[44] Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease [J]. ATHEROSCLEROSIS, 1999, 144 (01) : 177 - 184

[45] LOW HIGH-DENSITY-LIPOPROTEIN LEVEL IS ASSOCIATED WITH INCREASED RESTENOSIS RATE AFTER CORONARY ANGIOPLASTY [J]. CIRCULATION, 1992, 85 (04) : 1279 - 1285

[46] Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins - An idea whose time for testing is coming, Part I [J]. CIRCULATION, 2001, 104 (19) : 2376 - 2383

[47] Slyper A, 2005, AM J CLIN NUTR, V81, P376

[48] Mechanism of action of fibrates on lipid and lipoprotein metabolism [J]. CIRCULATION, 1998, 98 (19) : 2088 - 2093

[49] Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (01) : 12 - 20

[50] Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [J]. CIRCULATION, 2004, 110 (23) : 3512 - 3517